Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600611 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
A Phase 3 study, sponsored by Motif Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT02600611 is a Phase 3 study that has completed, run by Motif Bio. The registered enrollment target is 600 participants.
The verdict
NCT02600611, a Phase 3 study, has completed, sponsored by Motif Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
Interventions
- DRUG vancomycin
- DRUG iclaprim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2017-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02600611
The ClinicalTrials.gov registry entry for NCT02600611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Motif Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vancomycin is the first listed.
NCT02600611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02600611 about?
NCT02600611 is a clinical study titled "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1". This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
What is the current status of trial NCT02600611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2015-11-01. Estimated completion is 2017-01-30.
What interventions are being tested in trial NCT02600611?
The interventions under investigation include: vancomycin (DRUG), iclaprim (DRUG).
Who is sponsoring clinical trial NCT02600611?
This trial is sponsored by Motif Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.